Skip to Content
Translational Research Program (TRP)
Contact CIP
Show menu
Search this site
Last Updated: 10/10/18

Prostate SPOREs

In 2016, it is estimated that over 180,000 new cases of prostate cancer and over 26,000 deaths from this disease will be reported in the United States. As part of an NCI-wide program aimed at identifying new opportunities in prostate cancer research, the NCI now supports eight SPOREs in prostate cancer. These SPOREs are highly collaborative translational research teams, sharing resources and conducting inter-institutional clinical studies for the prevention, monitoring, and treatment of prostate cancer. The SPOREs in prostate cancer play a central role in advancing translational cancer research with academia, industry, other government agencies, and the international research community.

The SPOREs in prostate cancer developed a number of new scientific approaches to address prostate cancer. Accomplishments include the development of a number of new model systems for preclinical studies of prostate cancer and making advances that have been accepted for clinical practice, such as the Partin tables for staging, the Kattan nomograms for prognosis, the adaptation of PSA dynamics as surrogate markers for survival, and the introduction of a number of novel serum and tissue markers for detection and diagnosis, including the molecular profiling of various stages of this disease. Seminal developments emerging from the Prostate SPOREs include the discovery of ETS family gene translocations in prostate cancer, the first common casual gene translocation to be identified in a major human solid tumor, and the development of new therapeutic modalities, such as second-generation antiandrogens, which are now prolonging the lives of many individuals with prostate cancer.